Similarly, cetuximab, which targets the epidermal growth factor receptor (EGFR), enhances the effect of RSL3 in inducing ferroptosis in KRAS-mutant CRC cells by activating p38 MAPK and inhibiting the NRF2/HO-1 axis [40]. Here, KRAS is linked to colorectal carcinoma.